Acuitas Medical Limited, a Swansea, UK-based MRI technology developer, has received an investment of undisclosed amount from existing backers Finance Wales and Altima Partners.
The company intends to use the funds for clinical validation and product development of its fineSA™ software prior to full commercialization, QA and regulatory processes.
fineSA is a patented MRI technology for the early diagnosis of a range of diseases of the liver, lung and brain, together with breast cancer and osteoporosis. It can also play an important role in preclinical research and drug development, monitoring the effectiveness of treatment therapies over the various phases involved in bringing a drug to market.
Led by CEO and co-founder Peter E Taylor, Acuitas Medical collaborates with prominent research institutions to develop its software, including Emory University, Atlanta; Oxford NHS Trust; Ludwig Maximilians Universität (LMÜ) Munich; Cambridge Research Institute; Cambridge University; Oxford University; University of California at Santa Barbara and Swansea University.